
Reszon Diagnostics
Founded Year
2010Stage
Acquired | AcquiredValuation
$0000About Reszon Diagnostics
On June 8th, 2022, Reszon Diagnostics was acquired by Rubberex.1 million. Reszon Diagnostics develops and manufactures a portfolio of in vitro diagnostics rapid test kits and ELISA kits for medical professionals and clinical diagnostic markets worldwide. Its IVD rapid test kits allow medical professionals to diagnose disease quickly and accurately for early detection and prevention of diseases. The company was founded in 2010 and is based in Subang Jaya, Malaysia.
Missing: Reszon Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Reszon Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Reszon Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Reszon Diagnostics is included in 2 Expert Collections, including Health Monitoring & Diagnostics.
Health Monitoring & Diagnostics
702 items
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
Clinical Encounter Tech
625 items
Latest Reszon Diagnostics News
Nov 1, 2022
KUALA LUMPUR: Hextar Healthcare Bhd (HHB) (formerly known as Rubberex Corp (M) Bhd) in a filing Bursa Malaysia on Monday announced that it has completed the acquisition of a 100% equity interest in Reszon Diagnostics International Sdn Bhd (RDI).According to HHB’s executive director Goh Hsu-Ming, “Our acquisition of RDI andventure into the healthcare sector is timely as we enter endemicity, here in Malaysia and globally. Amidst higher health and safety awareness, personal protective equipment gears remain at the forefront of protection and defence.” By expanding its product offerings to include medical devices and test kits for various diseases, Goh reiterated that diversifying into healthcare is, “in line with HHB’s overall growth strategy of embarking on incomegenerating businesses that are complementary to the Group and sustainable for the long term.”Earlier, HHB also saw the emergence of new substantial shareholder, Revongen Corp Sdn Bhd, with a 16.2% stake in the company via the allotment of 176.6 million new shares as part of the acquisition settlement of RDI. Director and founder of RDI, Law Eng Lim, is enthusiastic on the prospects of the healthcare industry. He shares that the acquisition of RDI by HHB “is synergistic as we strengthen the group’s position in the broader healthcare business. Coming out of the pandemic, demand for such products and services by the health-conscious population is expected to drive the market higher.”HHB’s largest shareholder Datuk Eddie Ong Choo Meng remains fully supportive of thisventure and believes that the investment will contribute progressively to the future growth of HHB. “The prospects under healthcare are positive and we are committed to this business for the long term,” he added.
Reszon Diagnostics Frequently Asked Questions (FAQ)
When was Reszon Diagnostics founded?
Reszon Diagnostics was founded in 2010.
Where is Reszon Diagnostics's headquarters?
Reszon Diagnostics's headquarters is located at No. 12A Jalan TP5, Subang Jaya.
What is Reszon Diagnostics's latest funding round?
Reszon Diagnostics's latest funding round is Acquired.
Who are the investors of Reszon Diagnostics?
Investors of Reszon Diagnostics include Rubberex.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.